Biomarker & Intervention Discovery

GERD (Gastroesophageal Reflux Disease)

This page lists 8 druggable gene targets, 45 approved or trial-tested drug candidates and 15 recent clinical trials for GERD (Gastroesophageal Reflux Disease), with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Plain-language summary → New Treatments for GERD (2026): Vonoprazan & More

Research Tracker Chronic Disease Interventions GERD (Gastroesophageal Reflux Disease) Biomarker Atlas →

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
—
Gap size
—
Primary barrier
—

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

ATP4A 226CHRM3 280CLDN1 0HRH2 218IL8 152PTGS2 299TJP1 4TRPV1 160

ATP4A

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NIFEDIPINE ↑ activates Mechanistic DGIdb
EPIPREGNANOLONE SULPHATE ↑ activates Mechanistic DGIdb
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE ↓ inhibits Mechanistic DGIdb
PIOGLITAZONE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
HALOTHANE ↓ inhibits Mechanistic DGIdb
NN-DIMETHYL-D-ERYTHROSPHINGOSINE ↑ activates Mechanistic DGIdb
NA+ ↓ inhibits Mechanistic DGIdb
PREGNENOLONE SULPHATE ↑ activates Mechanistic DGIdb
(S)-LIQUIRITIGENIN ↓ inhibits Mechanistic DGIdb
ILAPRAZOLE ↓ inhibits Mechanistic DGIdb
CIM0216 ↑ activates Mechanistic DGIdb
NARINGENIN ↓ inhibits Mechanistic DGIdb
MAPROTILINE ↓ inhibits Mechanistic DGIdb
TEGOPRAZAN ↓ inhibits Mechanistic DGIdb
LA3+ ↓ inhibits Mechanistic DGIdb
ISOSAKURANETIN ↓ inhibits Mechanistic DGIdb
TROGLITAZONE ↓ inhibits Mechanistic DGIdb
SPHINGOSINE ↑ activates Mechanistic DGIdb
FEXUPRAZAN ↓ inhibits Mechanistic DGIdb
PENTAFLUORO-TRITYL CLOTRIMAZOLE ANALOGUE 29A ↑ activates Mechanistic DGIdb
GD3+ ↓ inhibits Mechanistic DGIdb
ROSIGLITAZONE ↓ inhibits Mechanistic DGIdb
DIHYDROSPHINGOSINE ↑ activates Mechanistic DGIdb
PRIMIDONE ↓ inhibits Mechanistic DGIdb
2-APB ↓ inhibits Mechanistic DGIdb
OMEPRAZOLE MAGNESIUM ↓ inhibits Mechanistic DGIdb
CHLOROFORM ↓ inhibits Mechanistic DGIdb
MEFENAMIC ACID ↓ inhibits Mechanistic DGIdb
PANTOPRAZOLE SODIUM ↓ inhibits Mechanistic DGIdb
VONOPRAZAN FUMARATE ↓ inhibits Mechanistic DGIdb
RABEPRAZOLE ↓ inhibits Mechanistic DGIdb
OMEPRAZOLE ↓ inhibits Mechanistic 3800.0 nM (IC50) DGIdb
ESOMEPRAZOLE SODIUM ↓ inhibits Mechanistic DGIdb
LANSOPRAZOLE ↓ inhibits Mechanistic 398.11 nM (IC50) DGIdb
ESOMEPRAZOLE STRONTIUM ↓ inhibits Mechanistic DGIdb
DICLOFENAC SODIUM ↓ inhibits Mechanistic DGIdb
ABEPRAZAN ? unclear Mechanistic Open Targets
ESOMEPRAZOLE MAGNESIUM ? unclear Mechanistic Open Targets
RABEPRAZOLE SODIUM ? unclear Mechanistic Open Targets
DEXLANSOPRAZOLE ? unclear Mechanistic Open Targets

Showing top 40 of 226 agents ranked by evidence tier.

CHRM3

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TARAFENACIN ? unclear Mechanistic DGIdb
METHIXENE ? unclear Mechanistic DGIdb
OXYBUTYNIN ↓ inhibits Mechanistic DGIdb
CEVIMELINE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
ZAMIFENACIN ? unclear Mechanistic DGIdb
IMIDAFENACIN ↓ inhibits Mechanistic DGIdb
TIOTROPIUM ? unclear Mechanistic DGIdb
BENZQUINAMIDE ? unclear Mechanistic DGIdb
TOLTERODINE ↓ inhibits Mechanistic DGIdb
OCTOTROPINE METHYLBROMIDE ↓ inhibits Mechanistic DGIdb
SOLIFENACIN ? unclear Mechanistic DGIdb
DOXEPIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1084941 ? unclear Mechanistic DGIdb
IPRATROPIUM CATION ↓ inhibits Mechanistic DGIdb
PROMAZINE ? unclear Mechanistic DGIdb
CLIDINIUM ↓ inhibits Mechanistic DGIdb
BATEFENTEROL ↓ inhibits Mechanistic DGIdb
BETHANECHOL CHLORIDE ↑ activates Mechanistic DGIdb
OLANZAPINE ? unclear Mechanistic DGIdb
OXYPHENCYCLIMINE ? unclear Mechanistic DGIdb
TRIDIHEXETHYL ? unclear Mechanistic DGIdb
ACETYLCHOLINE CHLORIDE ↑ activates Mechanistic DGIdb
METHACHOLINE CHLORIDE ↑ activates Mechanistic DGIdb
TRIDIHEXETHYL CHLORIDE ↓ inhibits Mechanistic DGIdb
CYCLOPENTOLATE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
REVEFENACIN ↓ inhibits Mechanistic DGIdb
PIPERTRAMINE ? unclear Mechanistic DGIdb
FESOTERODINE ↓ inhibits Mechanistic DGIdb
CCG-50014 ? unclear Mechanistic DGIdb
ATROPINE SULFATE ↓ inhibits Mechanistic DGIdb
PROMETHAZINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
ACLIDINIUM BROMIDE ↓ inhibits Mechanistic DGIdb
TROPICAMIDE ↓ inhibits Mechanistic DGIdb
DAROTROPIUM BROMIDE ↓ inhibits Mechanistic DGIdb
ACECLIDINE ? unclear Mechanistic DGIdb
SOLIFENACIN SUCCINATE ↓ inhibits Mechanistic DGIdb
DEXAMETHASONE ? unclear Mechanistic DGIdb
TIOTROPIUM BROMIDE ↓ inhibits Mechanistic DGIdb
TROSPIUM ↓ inhibits Mechanistic DGIdb
GLYCOPYRRONIUM ↓ inhibits Mechanistic DGIdb

Showing top 40 of 280 agents ranked by evidence tier.

CLDN1

UniProt Ensembl DGIdb Open Targets

Pipeline results not yet available for this target. Run the pipeline to populate.

HRH2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NIZATIDINE ↓ inhibits Mechanistic DGIdb
FAMOTIDINE ↓ inhibits Mechanistic DGIdb
RANITIDINE BISMUTH CITRATE ↓ inhibits Mechanistic DGIdb
BETAZOLE ? unclear Mechanistic DGIdb
MS31 ↓ inhibits Mechanistic DGIdb
RANITIDINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
BETAZOLE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
EPINASTINE ? unclear Mechanistic DGIdb
LAFUTIDINE ↓ inhibits Mechanistic DGIdb
HISTAMINE ? unclear Mechanistic 463.0 nM (EC50) DGIdb
TOLAZOLINE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
CIMETIDINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
EBROTIDINE ↓ inhibits Mechanistic DGIdb
DOXEPIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
METHANTHELINE BROMIDE ↓ inhibits Mechanistic DGIdb
ASENAPINE ? unclear Mechanistic DGIdb
CIMETIDINE ↓ inhibits Mechanistic DGIdb
MS8535 ↓ inhibits Mechanistic DGIdb
TOLAZOLINE ? unclear Mechanistic Open Targets
METHANTHELINE ? unclear Mechanistic Open Targets
RANITIDINE ? unclear Mechanistic Open Targets
VUF-5297 ↑ activates Mechanistic 696.0 nM (EC50) ChEMBL
CHEMBL72424 ↓ inhibits Mechanistic 10000.0 nM (Ki) ChEMBL
CHEMBL70603 ↓ inhibits Mechanistic 10000.0 nM (Ki) ChEMBL
CHEMBL44220 ↓ inhibits Mechanistic 19952.62 nM (Ki) ChEMBL
CHEMBL72571 ↓ inhibits Mechanistic 3981.07 nM (Ki) ChEMBL
CHEMBL310087 ↓ inhibits Mechanistic 12589.25 nM (Ki) ChEMBL
CHEMBL70811 ↓ inhibits Mechanistic 1584.89 nM (Ki) ChEMBL
CHEMBL72372 ↓ inhibits Mechanistic 1584.89 nM (Ki) ChEMBL
CHEMBL418470 ↑ activates Mechanistic 93.0 nM (EC50) ChEMBL
CHEMBL308717 ↓ inhibits Mechanistic 5011.87 nM (Ki) ChEMBL
BURIMAMIDE ↓ inhibits Mechanistic 3981.07 nM (Ki) ChEMBL
VUF-5296 ↑ activates Mechanistic 2500.0 nM (EC50) ChEMBL
CHEMBL305929 ↓ inhibits Mechanistic 3162.28 nM (Ki) ChEMBL
CHEMBL104994 ↓ inhibits Mechanistic 22000.0 nM (Ki) ChEMBL
CHEMBL107293 ↓ inhibits Mechanistic 380.0 nM (Ki) ChEMBL
CHEMBL102840 ↓ inhibits Mechanistic 2300.0 nM (Ki) ChEMBL
CHEMBL104808 ↓ inhibits Mechanistic 500.0 nM (Ki) ChEMBL
CHEMBL105071 ↓ inhibits Mechanistic 730.0 nM (Ki) ChEMBL
CHEMBL101634 ↓ inhibits Mechanistic 6200.0 nM (Ki) ChEMBL

Showing top 40 of 218 agents ranked by evidence tier.

IL8

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
VITAMIN A ? unclear Mechanistic DGIdb
FENTANYL CITRATE ? unclear Mechanistic DGIdb
ALPRAZOLAM ? unclear Mechanistic DGIdb
FENRETINIDE ? unclear Mechanistic DGIdb
RIBAVIRIN ? unclear Mechanistic DGIdb
RECOMBINANT INTERLEUKIN-1 ? unclear Mechanistic DGIdb
CIDOFOVIR ANHYDROUS ? unclear Mechanistic DGIdb
DIPYRIDAMOLE ? unclear Mechanistic DGIdb
TROGLITAZONE ? unclear Mechanistic DGIdb
LANSOPRAZOLE ? unclear Mechanistic DGIdb
IONOMYCIN ? unclear Mechanistic DGIdb
E319 ? unclear Mechanistic DGIdb
CEFTRIAXONE ? unclear Mechanistic DGIdb
CHLORDANE ? unclear Mechanistic DGIdb
FOSCARNET ? unclear Mechanistic DGIdb
ADAKITUG ↓ inhibits Mechanistic DGIdb
DANAZOL ? unclear Mechanistic DGIdb
D-ALPHA-TOCOPHEROL ACETATE ? unclear Mechanistic DGIdb
DICYCLOHEXYLCARBODIIMIDE ? unclear Mechanistic DGIdb
RO 31-8220 ? unclear Mechanistic DGIdb
BEVACIZUMAB ? unclear Mechanistic DGIdb
BROXURIDINE ? unclear Mechanistic DGIdb
TRETINOIN ? unclear Mechanistic DGIdb
ALL-TRANS-RETINAL ? unclear Mechanistic DGIdb
METHIMAZOLE ? unclear Mechanistic DGIdb
DEOXYSPERGUALIN ? unclear Mechanistic DGIdb
PAZOPANIB ? unclear Mechanistic DGIdb
OMEPRAZOLE ? unclear Mechanistic DGIdb
ALPHA-TOCOPHEROL ACETATE ? unclear Mechanistic DGIdb
MEDROXYPROGESTERONE ACETATE ? unclear Mechanistic DGIdb
ASPIRIN ? unclear Mechanistic DGIdb
TETRADECANOYLPHORBOL ACETATE ? unclear Mechanistic DGIdb
PENTOXIFYLLINE ? unclear Mechanistic DGIdb
PYROGALLOL ? unclear Mechanistic DGIdb
KLEBSIELLA PNEUMONIAE GLYCOPROTEIN ? unclear Mechanistic DGIdb
ABX-IL8 ↓ inhibits Mechanistic DGIdb
FLUOROURACIL ? unclear Mechanistic DGIdb
BIOFLAVONOID ? unclear Mechanistic DGIdb
LEFLUNOMIDE ? unclear Mechanistic DGIdb
QUESTIOMYCIN B ? unclear Mechanistic DGIdb

Showing top 40 of 152 agents ranked by evidence tier.

PTGS2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CARPROFEN ↓ inhibits Mechanistic 102.0 nM (IC50) DGIdb
INDOMETHACIN SODIUM ↓ inhibits Mechanistic DGIdb
DARBUFELONE ? unclear Mechanistic DGIdb
MEFENAMIC ACID ↓ inhibits Mechanistic DGIdb
MECLOFENAMATE SODIUM ↓ inhibits Mechanistic DGIdb
DICLOFENAC SODIUM ↓ inhibits Mechanistic DGIdb
CAPECITABINE ? unclear Mechanistic DGIdb
PIRPROFEN ↓ inhibits Mechanistic DGIdb
ESFLURBIPROFEN ↓ inhibits Mechanistic DGIdb
SULFASALAZINE ↓ inhibits Mechanistic DGIdb
BROMFENAC ? unclear Mechanistic DGIdb
IBUPROFEN, SODIUM SALT ↓ inhibits Mechanistic DGIdb
ALOXIPRIN ↓ inhibits Mechanistic DGIdb
TENOXICAM ? unclear Mechanistic DGIdb
FLURBIPROFEN ↓ inhibits Mechanistic DGIdb
SALICYLIC ACID ? unclear Mechanistic DGIdb
ATENOLOL ? unclear Mechanistic DGIdb
DEXKETOPROFEN ↓ inhibits Mechanistic DGIdb
ETORICOXIB ↓ inhibits Mechanistic DGIdb
LUMIRACOXIB ↓ inhibits Mechanistic DGIdb
SUPROFEN ↓ inhibits Mechanistic DGIdb
NS-398 ? unclear Mechanistic DGIdb
NABUMETONE ↓ inhibits Mechanistic DGIdb
URSOLIC ACID ? unclear Mechanistic DGIdb
IBUPROFEN LYSINE ↓ inhibits Mechanistic DGIdb
ACECLOFENAC ↓ inhibits Mechanistic DGIdb
IBUFENAC ↓ inhibits Mechanistic DGIdb
BALSALAZIDE ? unclear Mechanistic DGIdb
DIFLUNISAL ↓ inhibits Mechanistic DGIdb
BALSALAZIDE DISODIUM ↓ inhibits Mechanistic DGIdb
VACCINE ? unclear Mechanistic DGIdb
KETOROLAC TROMETHAMINE ↓ inhibits Mechanistic DGIdb
BENZYDAMINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TIAPROFENIC ACID ? unclear Mechanistic DGIdb
RALOXIFENE HYDROCHLORIDE ? unclear Mechanistic DGIdb
NAPROXCINOD ↓ inhibits Mechanistic DGIdb
IGURATIMOD ↓ inhibits Mechanistic DGIdb
ETODOLAC ↓ inhibits Mechanistic DGIdb
DICLOFENAC ETALHYALURONATE SODIUM ↓ inhibits Mechanistic DGIdb
ROFECOXIB ↓ inhibits Mechanistic 530.0 nM (IC50) DGIdb

Showing top 40 of 299 agents ranked by evidence tier.

TJP1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DEXAMETHASONE ? unclear Mechanistic DGIdb
RISPERIDONE ? unclear Mechanistic DGIdb
DEHYDRATED ALCOHOL ? unclear Mechanistic DGIdb
GENISTEIN ? unclear Mechanistic DGIdb

TRPV1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
STREPTOZOCIN ? unclear Mechanistic DGIdb
BENZYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
ACETAMINOPHEN ↑ activates Mechanistic DGIdb
POLYGODIAL ? unclear Mechanistic DGIdb
PROPOFOL ? unclear Mechanistic DGIdb
SAF312 ↓ inhibits Mechanistic DGIdb
GRC-15300 ? unclear Mechanistic DGIdb
AZD1386 ↓ inhibits Mechanistic DGIdb
TIVANISIRAN ↓ inhibits Mechanistic DGIdb
MAVATREP ↓ inhibits Mechanistic DGIdb
MR-1817 ↓ inhibits Mechanistic DGIdb
FERRUGINENE B ? unclear Mechanistic DGIdb
CAPSAICIN ↑ activates Mechanistic 19.95 nM (EC50) DGIdb
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic DGIdb
PHENETHYLISOTHIOCYANATE ? unclear Mechanistic DGIdb
VOACANGINE ? unclear Mechanistic DGIdb
RESINIFERATOXIN ↑ activates Mechanistic 23.1 nM (Ki) DGIdb
DWP05195 ↓ inhibits Mechanistic DGIdb
XEN-D0501 ↓ inhibits Mechanistic DGIdb
PAC-14028 ↓ inhibits Mechanistic DGIdb
SB-705498 ↓ inhibits Mechanistic DGIdb
MASOPROCOL ? unclear Mechanistic DGIdb
ALLYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
NGD-8243 ↓ inhibits Mechanistic DGIdb
GRC-6211 ↓ inhibits Mechanistic DGIdb
RESERPINE ? unclear Mechanistic DGIdb
NABIXIMOLS ? unclear Mechanistic DGIdb
A425619 ? unclear Mechanistic DGIdb
PHE377 ↓ inhibits Mechanistic DGIdb
ANTISENSE OLIGONUCLEOTIDES ? unclear Mechanistic DGIdb
WORTMANNIN ? unclear Mechanistic DGIdb
JTS-653 ↓ inhibits Mechanistic DGIdb
LEVODOPA ? unclear Mechanistic DGIdb
AMG517 ↓ inhibits Mechanistic DGIdb
CAPSAZEPINE ? unclear Mechanistic 120.0 nM (Ki) DGIdb
ZUCAPSAICIN ↑ activates Mechanistic DGIdb
INDOMETHACIN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL191534 ? unclear Mechanistic DGIdb
ABT-102 ↓ inhibits Mechanistic DGIdb
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb

Showing top 40 of 160 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is GERD (Gastroesophageal Reflux Disease): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) Completed
NCT07037875 Phase: 3 Started: 2025-09-11

The goal of this clinical trial is to find out how well linaprazan glurate can heal erosive esophagitis (EE) caused by gastroesophageal reflux disease (GERD), compared to lansoprazole, a commonly used medication. Researchers will also evaluate whether linaprazan glurate: * Reduces heartburn symptoms...

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease Completed
NCT05587322 Phase: 3 Started: 2022-09-06

The objective of the Treatment Phase of the study is to evaluate the safety and efficacy of 4 weeks of once daily oral administration of BLI5100 low dose, BLI5100 high dose, or placebo in patients with NERD. The objective of the Extension Phase of the study is to evaluate the safety of extended expo...

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. Completed
NCT05267613 Phase: 3 Started: 2022-07-01

The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.

A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks Recruiting
NCT07752407 Phase: 3 Started: 2026-09-25

The main objective is to assess the efficacy of vonoprazan (10 mg as needed) compared to placebo (as needed) in relief of episodic heartburn at 2 hours that is sustained for 24 hours over 12 weeks of treatment in participants with non-erosive gastroesophageal reflux disease (GERD).

Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease Completed
NCT07326904 Phase: 3 Started: 2024-08-28

The goal of this clinical trial was to evaluate the effectiveness and safety of fexuprazan 40 mg for relieving symptoms of gastroesophageal reflux disease (GERD) in adults. The study also compared fexuprazan with esomeprazole 40 mg, a commonly used treatment for GERD. The main questions this study a...

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old Completed
NCT02616302 Phase: 2 Started: 2023-02-20

Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus ...

Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD Completed
NCT05556824 Phase: 2 Started: 2023-03-03

This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.

Alginate vs Sucralfate for GERD Symptomatic Relief Completed
NCT07310927 Phase: 2/3 Started: 2025-04-01

Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal disorder characterized by the regurgitation of gastric contents into the esophagus.It can also present in an atypical manner such as chest pain, dental erosions, chronic cough, laryngitis, or asthma i.e. extra gastroesophageal symp...

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole Completed
NCT05055128 Phase: 2 Started: 2021-08-11

This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically unhealed (LA grades A or B) after 8 weeks history of standard treatment hea...

Comparison of Esomeprazole Versus Vonoprazan in Gastroesophageal Reflux Disease Completed
NCT07563491 Phase: N/A Started: 2025-01-01

Local literature is deprived of data comparing the effectiveness of esomeprazole and vonoprazan in patients with gastroesophageal reflux disease (GERD). This study was planned with the objective of comparing the effectiveness of esomeprazole versus vonoprazan in patients diagnosed with GERD.

Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM Recruiting
NCT06955520 Phase: N/A Started: 2025-04-30

Peroral Endoscopic Myotomy (POEM) is a well-established treatment for achalasia; however, it is frequently associated with gastroesophageal reflux disease (GERD), with many patients developing LA grade B or higher esophagitis. Proton pump inhibitors (PPIs) like Esomeprazole are the standard treatmen...

A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks Recruiting
NCT06953986 Phase: N/A Started: 2025-12-20

Primary Objective • To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily. Secondary Objectives * To assess the improvement in reflux symptoms using the GERD-Q score at 8 we...

Study to Evaluate the Effect of Food on the Pharmacokinetics and Pharmacodynamics Characteristics in Healthy Adult Volunteers Completed
NCT07364838 Phase: 1 Started: 2024-11-21

A Randomized, Open-label, Oral in healthy volunteers

Treatment of Gastroesophageal Reflux Disease in Infants Recruiting
NCT06255886 Phase: 4 Started: 2025-10-27

Gastroesophageal reflux disease in infants is not fully understood. Infants are prescribed medical treatments that may not be effective or that contribute to adverse side effects and lead to concerns and expenses for the parents and healthcare system. Current guidelines recommend cow-milk-protein fr...

Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease Completed
NCT06945237 Phase: N/A Started: 2025-04-24

Gastroesophageal reflux disease (GERD) is a common chronic digestive system disorder with a high prevalence and a notably increasing trend. It imposes significant costs in terms of treatment expenses and impacts patients' quality of life. Acid suppression remains the primary treatment for GERD. Howe...

Agents Found By Disease-Level Search

Searched directly from “GERD (Gastroesophageal Reflux Disease)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

45 agents shown (approved or with trial evidence) — 39 not found by the gene-target search above.

Esomeprazole

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT04329000 NCT00317044 NCT00317044

pantoprazole

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00362609 NCT00307944 NCT01887743

Lansoprazole

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01990339 NCT01135368

Vonoprazan

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT05366738 NCT05366738

Dexlansoprazole

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02616302 NCT00627016

Esomeprazole 40 mgNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT04568772 NCT04329000

lesogaberan (AZD3355)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00757419

EG Scan II (transnasal endoscopy)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02066233

Standard EndoscopyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02066233

Lap Nissen fundoplication with division of short gastric vesselsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00852098

Laparoscopic Nissen fundoplication without division of short gastric vesselsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00852098

Standard dose (once daily) PPI plus low-dose antidepressantNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251732

Rabeprazole , placebo, placeboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251732

gastroenteroanastomosis simultaneous to vertical sleeve gastrectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07537244

vertical sleeve gastrectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07537244

NortriptylineNOT in gene-target list

Phase 2/3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01065649

Thickened infant formulaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02710955

Dexrabeprazole 10 mg Enteric-Coated TabletsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02689999

Omeprazole

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00256737

AciphexNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00204698

DIMAC02NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02789800

Atovaquone / Proguanil 250/100 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04568772

Tegoprazan 50 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04568772

Vonoprazan 20 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04568772

YYD601 40mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03943992

Nexium 40mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03943992

Laparoscopic traditional bilateral approachNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07252115

Intravenous FamotidineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06241183

Oral Maalox/ MylantaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06241183

patients with GERD after LSGNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05416645

Esophageal studiesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05180253

Endoscopic gastroplicationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00235677

Alginate-antacid groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03516188

Non antacid alginate groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03516188

CKD-381NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03211143

NexiumNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03211143

Tracheal LavageNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00865995

sleeve gastrectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04994665

sleeve gastrectomy with omentopexyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04994665

One Anastomosis Gastric Bypass (OAGB)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04422405

ZegeridNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01710995

LosecNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01710995

AG1321001(drug)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00380315

colesevelam (IW-3718)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT02030925

commercially available lansoprazoleNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03015610